Targeting the IGF1 axis in cancer proliferation
- PMID: 19663648
- DOI: 10.1517/14728220903201702
Targeting the IGF1 axis in cancer proliferation
Abstract
The IGF network of ligands, cell-surface receptors and IGF-binding proteins has important roles at multiple levels, including the cellular, organ and organism levels. The IGF system mediates growth, differentiation and developmental processes, and is also involved in various metabolic activities. Dysregulation of IGF system expression and action is linked to diverse pathologies, ranging from growth deficits to cancer development. Targeting of the IGF axis emerged in recent years as a promising therapeutic approach in conditions in which the IGF system is involved. Specific IGF1 receptor (IGF1R) targeting, in particular, produced the best experimental and clinical results so far, and generated significant optimism in the field. This review provides a basic analysis of the role of the IGF1R in cancer biology and explores the functional interactions between the IGF signaling pathways and various cancer genes (e.g., oncogenes, tumor suppressors). In addition, we review a number of specific malignancies in which the IGF system is involved and summarize recent data on preclinical and clinical studies employing IGF1R-targeted modalities.
Similar articles
-
Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin.Cancer Res. 2007 Jan 1;67(1):391-7. doi: 10.1158/0008-5472.CAN-06-1712. Cancer Res. 2007. PMID: 17210722
-
Tumor suppressors govern insulin-like growth factor signaling pathways: implications in metabolism and cancer.Oncogene. 2012 May 31;31(22):2703-14. doi: 10.1038/onc.2011.447. Epub 2011 Oct 3. Oncogene. 2012. PMID: 21963847 Review.
-
Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway--therapeutic perspectives in cancer.Nat Clin Pract Oncol. 2007 Oct;4(10):591-602. doi: 10.1038/ncponc0934. Nat Clin Pract Oncol. 2007. PMID: 17898809 Review.
-
Resistance pathways relevant to insulin-like growth factor-1 receptor-targeted therapy.Curr Opin Investig Drugs. 2009 Oct;10(10):1032-40. Curr Opin Investig Drugs. 2009. PMID: 19777391 Review.
-
Development of molecular agents for IGF receptor targeting.Horm Metab Res. 2003 Nov-Dec;35(11-12):843-9. doi: 10.1055/s-2004-814158. Horm Metab Res. 2003. PMID: 14710367 Review.
Cited by
-
Generation and screening of monoclonal antibodies for immunoPET imaging of IGF1R in prostate cancer.Mol Pharm. 2014 Oct 6;11(10):3624-30. doi: 10.1021/mp5003637. Epub 2014 Sep 4. Mol Pharm. 2014. PMID: 25157758 Free PMC article.
-
Identifying the mechanisms underlying the protective effect of tetramethylpyrazine against cisplatin‑induced in vitro ototoxicity in HEI‑OC1 auditory cells using gene expression profiling.Mol Med Rep. 2020 Dec;22(6):5053-5068. doi: 10.3892/mmr.2020.11631. Epub 2020 Oct 23. Mol Med Rep. 2020. PMID: 33174043 Free PMC article.
-
Insulin-like growth factor signaling regulates the timing of sensory cell differentiation in the mouse cochlea.J Neurosci. 2011 Dec 7;31(49):18104-18. doi: 10.1523/JNEUROSCI.3619-11.2011. J Neurosci. 2011. PMID: 22159122 Free PMC article.
-
Hallmarks of cancer: The insulin-like growth factors perspective.Front Oncol. 2022 Nov 21;12:1055589. doi: 10.3389/fonc.2022.1055589. eCollection 2022. Front Oncol. 2022. PMID: 36479090 Free PMC article. Review.
-
Proteomic analysis of combined IGF1 receptor targeted therapy and chemotherapy identifies signatures associated with survival in breast cancer patients.Oncotarget. 2020 Apr 28;11(17):1515-1530. doi: 10.18632/oncotarget.27566. eCollection 2020 Apr 28. Oncotarget. 2020. PMID: 32391121 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous